Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients

Clinical Microbiology and Infection

Volumn 21, Issue 11, 2015, Pages 998.e9-998.e15

  Erb, S ^a   Frei, R ^a   Stranden A M ^a   Dangel, M ^a   Tschudin Sutter, S ^a   Widmer, A F ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Clostridium difficile; Enzyme immunoassay; Fecal toxin A B; Immunocompromised; Toxigenic culture

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PREDNISONE; VANCOMYCIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG MEGADOSE; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; LABORATORY DIAGNOSIS; LABORATORY TEST; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; TERTIARY CARE CENTER; WORKLOAD; ADOLESCENT; CHEMISTRY; CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; CYTOLOGY; ENTEROCOLITIS; EVALUATION STUDY; FECES; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CYTOLOGICAL TECHNIQUES; ENTEROCOLITIS; ENTEROTOXINS; FECES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84945475790     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.07.016     Document Type: Article

References (37)

1. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
2. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14:929-931.
3. Bartlett J.G. Clostridium difficile-associated enteric disease. Curr Infect Dis Rep 2002, 4:477-483.
4. Leffler D.A., Lamont J.T. Clostridium difficile infection. N Engl J Med 2015, 372:1539-1548.
5. Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014, 20(Suppl. 2):1-26.
6. Goldenberg S.D., French G.L. Diagnostic testing for Clostridium difficile: a comprehensive survey of laboratories in England. J Hosp Infect 2011, 79:4-7.
7. Wilcox M.H. Laboratory diagnosis of Clostridium difficile infection: in a state of transition or confusion or both?. J Hosp Infect 2011, 79:1-3.
8. Crobach M.J., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009, 15:1053-1066.
9. Barbut F., Delmee M., Brazier J.S., et al. A European survey of diagnostic methods and testing protocols for Clostridium difficile. Clin Microbiol Infect 2003, 9:989-996.
10. Delmee M., Van Broeck J., Simon A., Janssens M., Avesani V. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 2005, 54:187-191.
11. Humphries R.M., Uslan D.Z., Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol 2013, 51:869-873.
12. Tenover F.C., Baron E.J., Peterson L.R., Persing D.H. Laboratory diagnosis of Clostridium difficile infection: can molecular amplification methods move us out of uncertainty?. J Mol Diagn 2011, 13:573-582.
13. Brecher S.M., Novak-Weekley S.M., Nagy E. Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon. Clin Infect Dis 2013, 57:1175-1181.
14. Fenner L., Widmer A.F., Goy G., Rudin S., Frei R. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol 2008, 46:328-330.
15. Barbut F., Surgers L., Eckert C., et al. Does a rapid diagnosis of Clostridium difficile infection impact on quality of patient management?. Clin Microbiol Infect 2014, 20:136-144.
16. Bagdasarian N., Rao K., Malani P.N. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015, 313:398-408.
17. Planche T.D., Davies K.A., Coen P.G., et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 2013, 13:936-945.
18. Kaltsas A., Simon M., Unruh L.H., et al. Clinical and laboratory characteristics of Clostridium difficile infection in patients with discordant diagnostic test results. J Clin Microbiol 2012, 50:1303-1307.
19. Baker I., Leeming J.P., Reynolds R., Ibrahim I., Darley E. Clinical relevance of a positive molecular test in the diagnosis of Clostridium difficile infection. J Hosp Infect 2013, 84:311-315.
20. Longtin Y., Trottier S., Brochu G., et al. Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program. Clin Infect Dis 2013, 56:67-73.
21. Leekha S., Aronhalt K.C., Sloan L.M., Patel R., Orenstein R. Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. Am J Infect Control 2013, 41:390-393.
22. Fenner L., Frei R., Gregory M., Dangel M., Stranden A., Widmer A.F. Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007. Eur J Clin Microbiol Infect Dis 2008, 27:1201-1207.
23. Stubbs S.L., Brazier J.S., O'Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999, 37:461-463.
24. Bauer M.P., Kuijper E.J., van Dissel J.T. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009, 15:1067-1079.
25. McDonald L.C., Coignard B., Dubberke E., et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28:140-145.
26. McPherson S., Rees C.J., Ellis R., Soo S., Panter S.J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006, 49:640-645.
27. Callejas-Diaz A., Gea-Banacloche J.C. Clostridium difficile: deleterious impact on hematopoietic stem cell transplantation. Curr Hematol Malig Rep 2014, 9:85-90.
28. Kamboj M., Son C., Cantu S., et al. Hospital-onset Clostridium difficile infection rates in persons with cancer or hematopoietic stem cell transplant: a C3IC network report. Infect Control Hosp Epidemiol 2012, 33:1162-1165.
29. Trifilio S.M., Pi J., Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:405-409.
30. Polage C.R., Chin D.L., Leslie J.L., Tang J., Cohen S.H., Solnick J.V. Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 2012, 74:369-373.
31. Koo H.L., Van J.N., Zhao M., et al. Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol 2014, 35:667-673.
32. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984, 6(Suppl. 1):S235-S241.
33. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992, 15:573-581.
34. Selinger C.P., Greer S., Sutton C.J. Is gastrointestinal endoscopy a risk factor for Clostridium difficile associated diarrhea?. Am J Infect Control 2010, 38:581-582.
35. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009, 58:403-410.
36. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
37. Petrella L.A., Sambol S.P., Cheknis A., et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 2012, 55:351-357.